| Outcome Measures: |
Primary: Change in Glycated haemoglobin (HbA1c ), Percent-points, From baseline (week 0) to End of Study visit (V3) (week 34-44) | Secondary: Relative change in body weight, Percent, From baseline (week 0) to End of Study visit (V3) (week 34-44)|Absolute change in body weight, Kilogram (Kg), From baseline (week 0) to End of Study visit (V3) (week 34-44)|HbA1c <7% (Yes/No), Percentage of patients achieving or not achieving the target value., End of Study visit (V3) (week 34-44)|HbA1c reduction >=1%-points and body weight reduction of >=5% (Yes/No), Percentage of patients achieving or not achieving the reduction., From baseline (week 0) to End of Study visit (V3) (week 34-44)|HbA1c reduction >=1%-points and body weight reduction of >=3% (Yes/No), Percentage of patients achieving or not achieving the reduction., From baseline (week 0) to End of Study visit (V3) (week 34-44)|Diabetes Treatment Satisfaction Questionnaire, change (DTSQc), relative treatment satisfaction, The change version (DTSQc) has the same 8 items as the status version but is reworded to direct the patients to rate their change in treatment satisfaction compared to before being treated with oral semaglutide. Each question is scored on a scale of -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change., End of Study visit (V3) (week 34-44)|Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction, The status version (DTSQs) provides a measure of how satisfied patients are with their current diabetes treatment. It consists of 8 questions, which are to be answered on a Likert scale from 0 to 6 (0 = very dissatisfied to 6 = very satisfied). Six questions are summed to produce a total Treatment Satisfaction score. The remaining two questions are concerning perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia, respectively., From baseline (week 0) to End of Study visit (V3) (week 34-44)
|
